Disclosures: Puru Rattan: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Nadim Mahmud: Nothing to Disclose 1471 A BALANCING ACT: THE LIFE-SAVING POTENTIAL AND DILEMMA OF LIVER TRANSPLANTATION AS AN ENDPOINT IN ALCOHOL-ASSOCIATED HEPATITIS TRIALS Aparna Goel 1 Allison Kwong 1 Lance Stein 2 Alexandre LOUVET 3 Sanjaya Satapathy 4 Ashwini Mehta 5 Steven Flamm 6 Costica Aloman 7 Julie Thompson 8 Amon Asgharpour 9 Daniel Ganger 10 Alexander Kuo 11 Fedja Rochling 12 Nikolaos Pyrsopoulos 13 Mitchell Shiffman 14 Christina Blevins 15 Julie Fergus 16 Deborah Scott 17 William Krebs 17 Jim Brown 17 Norman Sussman 15 WeiQi Lin 17 , 1 Stanford University Medical Center, 2 Piedmont Hospital Transplant Services, 3 Universitaire de Lille, 4 Northwell Health, 5 The Liver Institute (Methodist, Dallas), 6 Rush University Medical Center, 7 Westchester Medical Center, 8 University of Minnesota, 9 Virginia Commonwealth University, 10 Northwestern Memorial Hospital, 11 Cedars-Sinai Medical Center, 12 Nebraska Medical Center, 13 Rutgers, 14 Bon Secours, 15 Durect Corporation, 16 Durect Corporate, 17 Durect Background: Alcohol- associated hepatitis (AH) is an acute form of alcohol-associated liver disease (ALD) with a high 90-day mortality
Older Patients Older patients should take OXONEG INJECTION 1 under medical supervision as they may be more susceptible to its side effects
Biomed Res (Tokyo Japan)
David Sinclair: Well- Tom Brunner: You mentioned five factors that our doctors tell us
Beyond physical energy, the brain is one of the most metabolically demanding organs in the body, consuming roughly 20% of all ATP produced
The needle did not hurt at all
